================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 2, 2005 - -------------------------------------------------------------------------------- Date of Report (Date of earliest event reported) ORAGENICS, INC. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Florida 000-50614 59-3410522 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 13200 Progress Boulevard Alachua, Florida 32615 - -------------------------------------------------------------------------------- (Address of principal executive offices including zip code) (386) 418-4018 - -------------------------------------------------------------------------------- Registrant's telephone number, including area code None - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) ================================================================================ ITEM 8.01 OTHER EVENTS Oragenics, Inc. issued a press release to announce the start of a Phase I clinical study of its Replacement Therapy technology, a novel approach to the prevention of tooth decay. ITEM 9.01 FINANCIAL INFORMATION AND EXHIBITS Exhibit No. Description -------------------- ----------------------------------------------------- 99.1 Press Release -------------------- ----------------------------------------------------- SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 2nd day of May, 2005. ORAGENICS, INC. (Registrant) BY: /s/ Mento A. Soponis ----------------------------------------- Mento A. Soponis President and Chief Executive Officer